BRPI1009783A2 - compostos para o tratamento de distúrbios metabólicos. - Google Patents
compostos para o tratamento de distúrbios metabólicos.Info
- Publication number
- BRPI1009783A2 BRPI1009783A2 BRPI1009783A BRPI1009783A BRPI1009783A2 BR PI1009783 A2 BRPI1009783 A2 BR PI1009783A2 BR PI1009783 A BRPI1009783 A BR PI1009783A BR PI1009783 A BRPI1009783 A BR PI1009783A BR PI1009783 A2 BRPI1009783 A2 BR PI1009783A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- treatment
- metabolic disorders
- metabolic
- disorders
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000030159 metabolic disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0904285.4A GB0904285D0 (en) | 2009-03-12 | 2009-03-12 | Compounds for the treatment of metabolic disorders |
| PCT/GB2010/050441 WO2010103334A1 (en) | 2009-03-12 | 2010-03-12 | Compounds for the treatment of metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1009783A2 true BRPI1009783A2 (pt) | 2016-03-08 |
Family
ID=40600947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1009783A BRPI1009783A2 (pt) | 2009-03-12 | 2010-03-12 | compostos para o tratamento de distúrbios metabólicos. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20120059014A1 (pt) |
| EP (1) | EP2406251A1 (pt) |
| JP (1) | JP2012520283A (pt) |
| KR (1) | KR20110133045A (pt) |
| CN (1) | CN102395578A (pt) |
| AU (1) | AU2010222672A1 (pt) |
| BR (1) | BRPI1009783A2 (pt) |
| CA (1) | CA2754791A1 (pt) |
| CL (1) | CL2011002182A1 (pt) |
| EA (1) | EA201190207A1 (pt) |
| GB (1) | GB0904285D0 (pt) |
| IL (1) | IL215050A0 (pt) |
| MA (1) | MA33241B1 (pt) |
| MX (1) | MX2011009493A (pt) |
| PE (1) | PE20120218A1 (pt) |
| SG (1) | SG174363A1 (pt) |
| WO (1) | WO2010103334A1 (pt) |
| ZA (1) | ZA201107449B (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007007751A1 (de) * | 2007-02-16 | 2008-08-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102007035333A1 (de) * | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| JP2012530758A (ja) | 2009-06-24 | 2012-12-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物、医薬組成物及びそれに関する方法 |
| NZ596445A (en) | 2009-06-24 | 2013-04-26 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
| EP2547339A1 (en) | 2010-03-18 | 2013-01-23 | Boehringer Ingelheim International GmbH | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| GB201006167D0 (en) * | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
| WO2012066077A1 (en) | 2010-11-18 | 2012-05-24 | Prosidion Limited | 1,4 di substituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders |
| KR102001364B1 (ko) * | 2011-05-13 | 2019-07-22 | 어레이 바이오파마 인크. | Trka 키나제 저해제로서의 피롤리디닐 유레아 및 피롤리디닐 티오유레아 화합물 |
| AU2012267556B9 (en) | 2011-06-09 | 2017-05-11 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of GPR-119 |
| GB2497351A (en) * | 2011-12-09 | 2013-06-12 | Prosidion Ltd | Compounds useful as GPR119 agonists |
| HK1210825A1 (en) | 2012-07-11 | 2016-05-06 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| WO2016131198A1 (en) * | 2015-02-18 | 2016-08-25 | Eli Lilly And Company | Pyrazole compounds |
| EP3429591B1 (en) * | 2016-03-16 | 2023-03-15 | Kura Oncology, Inc. | Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6100042A (en) | 1993-03-31 | 2000-08-08 | Cadus Pharmaceutical Corporation | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
| GB9719496D0 (en) | 1997-09-13 | 1997-11-19 | Glaxo Group Ltd | G protien chimeras |
| CA2343046A1 (en) | 1998-09-01 | 2000-03-09 | Basf Aktiengesellschaft | Enhanced functional expression of g protein-coupled receptors |
| US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
| BRPI0418149A (pt) | 2003-12-24 | 2007-04-17 | Prosidion Ltd | derivados heterocìclicos como agonistas do receptor de gprc |
| WO2006067531A1 (en) | 2004-12-24 | 2006-06-29 | Prosidion Ltd | G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes |
| EP1838706A1 (en) | 2004-12-24 | 2007-10-03 | Prosidion Limited | G-protein coupled receptor agonists |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| US20090203676A1 (en) | 2005-06-30 | 2009-08-13 | Oscar Barba | G-protein Coupled Receptor Agonists |
| JP2008545008A (ja) | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Ｇｐｃｒアゴニスト |
| WO2007003960A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| NZ564759A (en) | 2005-06-30 | 2011-08-26 | Prosidion Ltd | GPCR agonists |
| NZ571869A (en) | 2006-04-06 | 2011-11-25 | Prosidion Ltd | Heterocyclic GPCR agonists |
| GB0607196D0 (en) | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
| GB0610746D0 (en) | 2006-06-01 | 2006-07-12 | Prosidion Ltd | Method of treatment |
| WO2007148185A2 (en) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
| CN101657471B (zh) * | 2006-12-06 | 2013-07-03 | 史密丝克莱恩比彻姆公司 | 二环化合物及其作为抗糖尿病药的用途 |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| AR064736A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr |
| CL2008000018A1 (es) * | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| BRPI0806498A2 (pt) | 2007-01-04 | 2014-04-22 | Prosidion Ltd | Agonistas gpcr piperidina |
| WO2008081208A1 (en) | 2007-01-04 | 2008-07-10 | Prosidion Limited | Piperidine gpcr agonists |
| US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| JP5489997B2 (ja) | 2007-07-19 | 2014-05-14 | シマベイ セラピューティクス， インコーポレーテッド | 糖尿病および代謝疾患の治療のためのＲＵＰ３またはＧＰＲｌ１９受容体のアゴニストとしてのＮ−アザ環状置換ピロール、ピラゾール、イミダゾール、トリアゾールおよびテトラゾール誘導体 |
| WO2009034388A1 (en) | 2007-09-10 | 2009-03-19 | Prosidion Limited | Compounds for the treatment of metabolic disorders |
| WO2009050971A1 (ja) | 2007-10-18 | 2009-04-23 | Nippon Mining & Metals Co., Ltd. | 金属被覆ポリイミド複合体及び同複合体の製造方法並びに電子回路基板の製造方法 |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| CN101621337B (zh) | 2008-06-30 | 2013-08-07 | 华为技术有限公司 | 一种时延调节装置与方法 |
| EA201170151A1 (ru) | 2008-07-10 | 2011-08-30 | Просидион Лимитед | Пиперидиниловые агонисты gpcr |
| GB0812641D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| ES2387865T3 (es) | 2008-07-10 | 2012-10-03 | Prosidion Ltd | Agonistas de GPCR de piperidina |
| GB0812648D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
-
2009
- 2009-03-12 GB GBGB0904285.4A patent/GB0904285D0/en not_active Ceased
-
2010
- 2010-03-12 CA CA2754791A patent/CA2754791A1/en not_active Abandoned
- 2010-03-12 CN CN2010800171471A patent/CN102395578A/zh active Pending
- 2010-03-12 WO PCT/GB2010/050441 patent/WO2010103334A1/en not_active Ceased
- 2010-03-12 EA EA201190207A patent/EA201190207A1/ru unknown
- 2010-03-12 EP EP10709053A patent/EP2406251A1/en not_active Withdrawn
- 2010-03-12 MX MX2011009493A patent/MX2011009493A/es unknown
- 2010-03-12 BR BRPI1009783A patent/BRPI1009783A2/pt not_active Application Discontinuation
- 2010-03-12 AU AU2010222672A patent/AU2010222672A1/en not_active Abandoned
- 2010-03-12 SG SG2011065802A patent/SG174363A1/en unknown
- 2010-03-12 US US13/255,531 patent/US20120059014A1/en not_active Abandoned
- 2010-03-12 JP JP2011553533A patent/JP2012520283A/ja active Pending
- 2010-03-12 MA MA34245A patent/MA33241B1/fr unknown
- 2010-03-12 KR KR1020117024019A patent/KR20110133045A/ko not_active Withdrawn
- 2010-03-12 PE PE2011001638A patent/PE20120218A1/es not_active Application Discontinuation
-
2011
- 2011-09-05 CL CL2011002182A patent/CL2011002182A1/es unknown
- 2011-09-08 IL IL215050A patent/IL215050A0/en unknown
- 2011-10-11 ZA ZA2011/07449A patent/ZA201107449B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2011009493A (es) | 2011-10-11 |
| CA2754791A1 (en) | 2010-09-16 |
| EP2406251A1 (en) | 2012-01-18 |
| CN102395578A (zh) | 2012-03-28 |
| WO2010103334A1 (en) | 2010-09-16 |
| CL2011002182A1 (es) | 2012-03-30 |
| JP2012520283A (ja) | 2012-09-06 |
| EA201190207A1 (ru) | 2012-04-30 |
| ZA201107449B (en) | 2012-06-27 |
| GB0904285D0 (en) | 2009-04-22 |
| SG174363A1 (en) | 2011-10-28 |
| IL215050A0 (en) | 2011-11-30 |
| MA33241B1 (fr) | 2012-05-02 |
| KR20110133045A (ko) | 2011-12-09 |
| AU2010222672A1 (en) | 2011-11-03 |
| PE20120218A1 (es) | 2012-03-19 |
| US20120059014A1 (en) | 2012-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTPA2020510I1 (lt) | Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui | |
| LTC2137143I2 (lt) | Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui | |
| PL2504005T3 (pl) | Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby | |
| BRPI0918527A2 (pt) | compostos para o tratamento de disturbios do cns | |
| BRPI1015569A2 (pt) | compostos úteis para o tratamento de doenças degenerativas e inflamatórias. | |
| SMP200900085B (it) | 3-imidazolil-indoli per il trattamento di malattieproliferative. | |
| PT2919796T (pt) | Utilização de akkermansia para o tratamento de distúrbios metabólicos | |
| BRPI1013426A2 (pt) | organismos para produção de 1,3-butanodiol | |
| BR112013014943A2 (pt) | compostos úteis para o tratamento de aids | |
| BRPI1007995A2 (pt) | orto-aminoamidas para o tratamento de cãncer. | |
| BRPI0911577A8 (pt) | derivados espiro-indol para o tratamento de doenças parasíticas. | |
| BRPI0813670A2 (pt) | Compostos para tratamento | |
| ZA201107449B (en) | Compounds for the treatment of metabolic disorders | |
| GB0904287D0 (en) | Compounds for the treatment of metabolic disorders | |
| BRPI1013245A2 (pt) | "composto para o tratamento de distúrbios metabólicos" | |
| BRPI0818170A2 (pt) | 5-cianotienopiridinas para o tratamento de tumores. | |
| BRPI0906606A2 (pt) | Tratamento terapêutico para condições do pulmão. | |
| BR112013015048A2 (pt) | composição para o tratamento de distúrbios metabólicos | |
| BRPI0920728A2 (pt) | Composição estabilizada para tratamento de psoríase | |
| BR112012002267A2 (pt) | compostos para o tratamento de inflamação. | |
| GB201006167D0 (en) | Compounds for the treatment of metabolic disorders | |
| BRPI0922216A2 (pt) | tratamento para glomerulonefrite | |
| BRPI0923862A2 (pt) | Compostos sulfonamida para o tratamento de distúrbios respiratórios | |
| GB201006166D0 (en) | Compounds for the treatment of metabolic disorders | |
| BRPI0909659A2 (pt) | tratamento para distúrbios relacionados oculares |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |